Parexel’s Yen For Expansion Yields Acquisition Of Japanese Bridging Study Experts
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal worth $60 mil. could bring in business from firms seeking drug approval in Japan.
You may also be interested in...
Parexel Ponders Acquisitions
Parexel is considering a strategic acquisition as it looks to utilize more than $100 mil. in excess cash
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Exec discusses the firm’s pulmonary arterial hypertension drug Tracleer and other endothelin receptor antagonists in Actelion’s pipeline.